Compare Ultrapar Participacoes S.A. (New) American Depositary Shares (Each representing one Common Share) (UGP) vs Vir Biotechnology Inc. Common Stock (VIR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ultrapar Participacoes S.A. (New) American Depositary Shares (Each representing one Common Share) vs Vir Biotechnology Inc. Common Stock — how do they compare? Ultrapar Participacoes S.A. (New) American Depositary Shares (Each representing one Common Share) trades at $7.8 (market cap $8.31B), while Vir Biotechnology Inc. Common Stock trades at $10.38 (market cap $1.76B). The key difference: Ultrapar Participacoes S.A. (New) American Depositary Shares (Each representing one Common Share) is far larger — about 4.7× Vir Biotechnology Inc. Common Stock's market cap, and Ultrapar Participacoes S.A. (New) American Depositary Shares (Each representing one Common Share) pays a 4.79% dividend while Vir Biotechnology Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Ultrapar Participacoes S.A. (New) American Depositary Shares (Each representing one Common Share) for 3 Days and Vir Biotechnology Inc. Common Stock for 0 Days on average.
| UGP | VIR | |
|---|---|---|
Market Cap | $8.31B | $1.76B |
Volume | 4,121,015 | 2,764,948 |
Sector | Energy | Health |
52-Week High | $7.90 | $11.78 |
52-Week Low | $3.63 | $5.12 |
Typical Hold Time | 3 Days | 0 Days |
Enterprise Value | $10.36B | $1.32B |
Dividend Yield | 4.79% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
UGP trades at $7.79, down 1.27% today but near recent 52-week highs. The stock shows strong technical momentum with bullish moving averages and solid fundamentals including 20.32% ROE and attractive valuation metrics (P/E 11.86, EV/EBITDA 5.1). Recent earnings beat expectations in Q2 2026 with $0.28 EPS versus $0.27 expected. The company demonstrated strong cash flow generation with $5.45B from operations in 2025, supporting its growth investments and financial discipline strategy outlined at recent investor events.
UGP presents a compelling value opportunity with improving profitability margins and revenue growth projected to reach $153.3B in 2026. However, risks include competitive pressures in oil and gas distribution, margin compression from rising costs, and dependence on energy price stability. Analyst consensus remains cautiously optimistic with 36% buy ratings but a $6.85 price target below current levels, suggesting potential near-term consolidation before further upside.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Ultrapar Participacoes S.A. (New) American Depositary Shares (Each representing one Common Share)
Ultrapar is a Brazilian company with fuel distribution, liquefied petroleum gas, and chemical businesses. Its consumer-facing operations include fuel and gas distribution brands.
Read more on UGP →About Vir Biotechnology Inc. Common Stock
Vir Biotechnology, Inc. is a US clinical-stage biopharmaceutical company that develops monoclonal antibody-based medicines to treat and prevent serious infectious diseases.
Read more on VIR →
